Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 6/2017

01-11-2017 | Original Article

Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis

Authors: Masataka Shiraki, Satoshi Tanaka, Hiroaki Suzuki, Satoko Ueda, Toshitaka Nakamura

Published in: Journal of Bone and Mineral Metabolism | Issue 6/2017

Login to get access

Abstract

Although once-yearly intravenous administration of zoledronic acid has been reported to inhibit bone resorption and increase bone mineral density, no studies have evaluated its effectiveness in treating osteoporosis in Japanese patients. Therefore, the purpose of this study was to investigate the pharmacokinetics and assess the safety of and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis. This was a single-administration study with a single-blind parallel-group design. The study participants were 24 Japanese patients with primary osteoporosis. The patients were divided into two groups, with each group receiving a single injection of zoledronic acid (4 or 5 mg). Pharmacokinetics and urinary excretion were then compared, and drug-related adverse events and changes in the levels of bone turnover markers were assessed at 12 months. Mean plasma concentrations of zoledronic acid peaked in both groups immediately after administration, and decreased to 1% or less of peak levels after 24 h. Noncompartmental analysis revealed that C max and the area under the curve from time zero to infinity increased in proportion to the dose. The levels of bone resorption and formation markers decreased from day 15 and from 3 months after administration respectively, and suppression of these markers remained constant for the entire study period. No serious adverse events were reported. There was no large difference between the 4- and 5-mg groups in terms of pharmacokinetics, changes in the levels of bone turnover markers, and safety profiles. This study demonstrated acceptable pharmacokinetics and changes in bone metabolism associated with zoledronic acid treatment in female Japanese osteoporosis patients. Both the 4-mg dose and the 5-mg dose demonstrated acceptable safety and sustained antiresorptive effects for the duration of the study.
Literature
1.
go back to reference Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps R, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209–257CrossRefPubMed Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps R, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209–257CrossRefPubMed
2.
go back to reference Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661CrossRefPubMed Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661CrossRefPubMed
3.
go back to reference Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K, Body JJ, Samsioe G, Felsenberg D, Fashola T, Sanna L, Ortmann CE, Trechsel U, Krasnow J, Eriksen EF, Garnero P (2007) Zoledronic acid efficacy and safety over 5 years in postmenopausal osteoporosis. Osteoporos Int 18:1211–1218CrossRefPubMed Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K, Body JJ, Samsioe G, Felsenberg D, Fashola T, Sanna L, Ortmann CE, Trechsel U, Krasnow J, Eriksen EF, Garnero P (2007) Zoledronic acid efficacy and safety over 5 years in postmenopausal osteoporosis. Osteoporos Int 18:1211–1218CrossRefPubMed
4.
go back to reference McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122–128CrossRefPubMed McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122–128CrossRefPubMed
5.
go back to reference Black DM, Delmas PD, Eastell R, Reid IR, Boonen S et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMed Black DM, Delmas PD, Eastell R, Reid IR, Boonen S et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMed
6.
go back to reference Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; for the HORIZON Recurrent Fracture Trial (2007) Zoledronic acid in reducing clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809CrossRefPubMed Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; for the HORIZON Recurrent Fracture Trial (2007) Zoledronic acid in reducing clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809CrossRefPubMed
7.
go back to reference Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Menesbrink P, Sambrook PH (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial. Lancet 373:1253–1263CrossRefPubMed Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Menesbrink P, Sambrook PH (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial. Lancet 373:1253–1263CrossRefPubMed
8.
go back to reference Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714–1723CrossRefPubMed Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714–1723CrossRefPubMed
9.
go back to reference Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009) Antifracture efficacy and reduction of mortality in relation to timing of first dose of zoledronic acid after hip fracture. J Bone Miner Res 24:1308–1313CrossRefPubMed Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009) Antifracture efficacy and reduction of mortality in relation to timing of first dose of zoledronic acid after hip fracture. J Bone Miner Res 24:1308–1313CrossRefPubMed
10.
go back to reference Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97CrossRefPubMed Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97CrossRefPubMed
11.
go back to reference Shiraki M, Nakamura T, Fukunaga M, Sone T, Usami A, Inoue T (2012) A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis—monthly (4 weeks) intravenous versus once weekly oral administrations. Curr Med Res Opin 28:1–11CrossRef Shiraki M, Nakamura T, Fukunaga M, Sone T, Usami A, Inoue T (2012) A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis—monthly (4 weeks) intravenous versus once weekly oral administrations. Curr Med Res Opin 28:1–11CrossRef
12.
go back to reference Hansen S, Hauge EM, Jensen JEB, Brixen K (2013) Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-qQCT. J Bone Miner Res 28:736–745CrossRefPubMed Hansen S, Hauge EM, Jensen JEB, Brixen K (2013) Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-qQCT. J Bone Miner Res 28:736–745CrossRefPubMed
13.
go back to reference Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H, Inoue T, Tomita A, Nagata Y, Nakashima M, Orimo H (1998) A placebo-controlled, single blind study to determine the alendronate dosage in postmenopausal Japanese patients with osteoporosis. Endocr J 45:191–201CrossRefPubMed Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H, Inoue T, Tomita A, Nagata Y, Nakashima M, Orimo H (1998) A placebo-controlled, single blind study to determine the alendronate dosage in postmenopausal Japanese patients with osteoporosis. Endocr J 45:191–201CrossRefPubMed
14.
go back to reference Novartis Pharma (2015) ZOMETA package insert, version 3, revised March 2015. Novartis Pharma, Tokyo Novartis Pharma (2015) ZOMETA package insert, version 3, revised March 2015. Novartis Pharma, Tokyo
15.
go back to reference Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337CrossRefPubMed Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337CrossRefPubMed
16.
go back to reference Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefPubMed Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefPubMed
18.
go back to reference Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235–242PubMed Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235–242PubMed
19.
go back to reference Coxon FP, Helfrich MH, Van′t Hof IR, Sebti S, Ralston SH, Hamilton A, Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467–1476CrossRefPubMed Coxon FP, Helfrich MH, Van′t Hof IR, Sebti S, Ralston SH, Hamilton A, Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467–1476CrossRefPubMed
20.
go back to reference Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627CrossRefPubMed Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627CrossRefPubMed
21.
go back to reference Novartis Pharmaceuticals (2015) ZOMETA prescribing information, revised January 2015. Novartis Pharmaceuticals, East Hanover Novartis Pharmaceuticals (2015) ZOMETA prescribing information, revised January 2015. Novartis Pharmaceuticals, East Hanover
22.
go back to reference Skerjanec A, Brenson J, Hsu C, Major P, Miller WH Jr, Ravera C, Schran H, Seaman J, Waldmeier F (2003) The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharm 43:154–162CrossRef Skerjanec A, Brenson J, Hsu C, Major P, Miller WH Jr, Ravera C, Schran H, Seaman J, Waldmeier F (2003) The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharm 43:154–162CrossRef
23.
go back to reference Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J (1999) A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14:1557–1561CrossRefPubMed Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J (1999) A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14:1557–1561CrossRefPubMed
24.
go back to reference Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharm 42:1228–1236CrossRef Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharm 42:1228–1236CrossRef
25.
go back to reference Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H, for the MOVER Study Group (2013) Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int 93:137–146CrossRefPubMedPubMedCentral Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H, for the MOVER Study Group (2013) Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int 93:137–146CrossRefPubMedPubMedCentral
26.
go back to reference Agrati C, Cimini E, Sacchi A, Bordoni V, Gioia C, Casetti R, Turchi F, Tripodi M, Federico Martini F (2009) Activated Vγ9Vδ2 T cells trigger granulocyte functions via MCP-2 release. J Immunol 182:522–529CrossRefPubMed Agrati C, Cimini E, Sacchi A, Bordoni V, Gioia C, Casetti R, Turchi F, Tripodi M, Federico Martini F (2009) Activated Vγ9Vδ2 T cells trigger granulocyte functions via MCP-2 release. J Immunol 182:522–529CrossRefPubMed
27.
go back to reference Sykiotis A, Papaioannou G, Mavropoulos J, Triantaphyllopoulou M, Papandroulaki F, Ktena V, Thanou S, Pardalakis A, Kaltsa A, Karga H (2014) Markers of inflammation after zoledronic acid redosing. J Bone Miner Metab 32:72–77CrossRefPubMed Sykiotis A, Papaioannou G, Mavropoulos J, Triantaphyllopoulou M, Papandroulaki F, Ktena V, Thanou S, Pardalakis A, Kaltsa A, Karga H (2014) Markers of inflammation after zoledronic acid redosing. J Bone Miner Metab 32:72–77CrossRefPubMed
28.
go back to reference Recker R, Stakkestad JA, Chesnut CH 3rd, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal. Bone 34:890–899CrossRefPubMed Recker R, Stakkestad JA, Chesnut CH 3rd, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal. Bone 34:890–899CrossRefPubMed
Metadata
Title
Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis
Authors
Masataka Shiraki
Satoshi Tanaka
Hiroaki Suzuki
Satoko Ueda
Toshitaka Nakamura
Publication date
01-11-2017
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 6/2017
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-016-0806-3

Other articles of this Issue 6/2017

Journal of Bone and Mineral Metabolism 6/2017 Go to the issue

List of Reviewers 2016-2017

List of Reviewers 2016–2017